Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposome Irinotecan + Platinum + Toripalimab + Anlotinib in ES-SCLC
NCT07376499Phase 2Not yet recruiting
- Sponsor
- China Medical University
- Start
- Jan 2026
- Primary completion
- Mar 2026
- Modality
- Lipid-based Nanoparticles, Small Molecules
01
Overview
A Phase 2 trial of irinotecan liposomal in small cell lung cancer (SCLC), sponsored by China Medical University. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
irinotecan liposomal
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07376499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07376499.